

An earnings surprise is the calculated difference between a firm's expected earnings numbers provided by Wall Street analysts and the actual reported numbers. A significant surprise factor often triggers sharp movements in the share price following the earnings release. For the most recent quarter, Rockwell Medical, Inc. (NASDAQ:RMTI) reported earnings per share of \$-0.05 for the fiscal period ending on 2015-06-30, an earnings surprise factor of 50%. The actual number was \$0.05 away from the brokerage firm consensus estimates. The sales surprise factor in per share dollar terms was \$2.096 for the most recent quarter or 19.3%.

Rockwell Medical, Inc. (NASDAQ:RMTI) is next scheduled to report quarterly earnings on 2015-11-09. Sell-side brokerages are expecting the company to report earnings of \$0.09 per share, according to the 6 covering analysts that were polled by Zacks Research. Shareholders will be closely monitoring how the estimates fluctuate leading up to the expected report date.

In terms of price targets, sell-side brokerage firms are projecting that the stock will reach the range of \$4-26. The average number taken from the 6 surveyed analysts, often referred to as the consensus price target, stands at \$15. Using a simplified 1 to 5 rating system produces a score of 2.55 for Rockwell Medical, Inc., where 1 represents a Strong Buy rating and 5 would indicate a Strong Sell rating. In taking a look at the recent analyst sentiment, three months ago the rating mean stood at 2.55. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...